LEADER 01893oam  2200517   450 
001 9910715500303321
005 20210315113606.0
035   $a(CKB)5470000002511036
035   $a(OCoLC)973950339
035   $a(EXLCZ)995470000002511036
100   $a20170202d2016      ua             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aMetformin use in patients with contraindications or precautions /$fMatthew J. Crowley [and eleven others]
210  1$aWashington, DC :$cDepartment of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service,$dSeptember 2016.
215   $a1 online resource (iii, 82 pages) $cillustrations
225 1 $aEvidence-based synthesis program
300   $a"September 2016."
300   $aIncludes errata and corrections.
320   $aIncludes bibliographical references (pages 40-45).
606   $aMetformin$xTherapeutic use$zUnited States
606   $aType 2 diabetes$xTreatment$zUnited States
606   $aAcidosis
615  0$aMetformin$xTherapeutic use
615  0$aType 2 diabetes$xTreatment
615  0$aAcidosis.
700   $aCrowley$b Matthew J.$01418430
712 02$aUnited States.$bDepartment of Veterans Affairs.$bHealth Services Research and Development Service,
712 02$aQuality Enhancement Research Initiative (U.S.)
712 02$aDurham VA Medical Center.$bEvidence-based Synthesis Program Center.
801  0$bNLM
801  1$bNLM
801  2$bMMU
801  2$bNLM
801  2$bOCLCQ
801  2$bOCLCO
801  2$bVT2
801  2$bOCLCA
801  2$bGPO
906   $aBOOK
912   $a9910715500303321
996   $aMetformin use in patients with contraindications or precautions$93529837
997   $aUNINA